AstraZeneca licensed up to eight experimental obesity and diabetes medications from CSPC Pharmaceutical Group, including the long-acting GLP-1R/GIPR agonist SYH2082 and three preclinical programs using CSPC's peptide discovery and LiquidGel once-monthly injectable technology. CSPC received $1.2B upfront, with up to $3.5B in R&D milestones and $13.8B in sales milestones plus royalties. AstraZeneca gets exclusive global rights outside Greater China.